AMPH — Amphastar Pharmaceuticals, Inc. stock price, charts and financials

QT64Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
23.62
-0.20-0.84%
AMPHQT64Amphastar Pharmaceuticals, Inc.·NASDAQ
23.62-0.84%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E13.98EPS (ttm)1.69Insider Own14.01%Shs Outstand44.09MPerf Week-0.67%
Market Cap1.04BForward P/E7.42EPS next Y3.18Insider Trans-0.47%Shs Float32.83MPerf Month8.65%
Enterprise Value1.43BPEG10.67EPS next Q0.86Inst Own-Short Float15.64%Perf Quarter25.57%
Income77.00MP/S1.43EPS this Y75.78%Inst Trans-Short Ratio10.50Perf Half Y20.88%
Sales730.00MP/B1.36EPS next Y7.09%ROA4.50%Short Interest5.13MPerf YTD-11.80%
Book/sh17.42P/C3.59EPS next 5Y1.31%ROE10.11%52W High29.52 -19.99%Perf Year-12.45%
Cash/sh6.58P/FCF6.86EPS past 3/5Y5.27% 134.54%ROIC5.90%52W Low16.65 41.86%Perf 3Y-48.98%
Dividend Est.-EV/EBITDA8.17Sales past 3/5Y13.00% 15.52%Gross Margin47.68%Volatility2.66% 2.91%Perf 5Y32.47%
Dividend TTM-EV/Sales1.96EPS Y/Y TTM-44.77%Oper. Margin15.66%ATR (14)0.71Perf 10Y25.24%
Dividend Ex-DateJun 11, 2010Quick Ratio1.71Sales Y/Y TTM-0.27%Profit Margin10.76%RSI (14)63.02Recom2.83
Dividend Gr. 3/5Y-Current Ratio2.40EPS Q/Q7.06%SMA202.81%Beta0.90Target Price21.25
Payout0.00%Debt/Eq0.82Sales Q/Q5.75%SMA5011.41%Rel Volume3.10Prev Close23.82
Employees1,976LT Debt/Eq0.82EarningsNov 05SMA2005.53%Avg Volume467.93KPrice23.62
IPO DateJun 25, 2014Option/ShortYes / YesEPS/Sales Surpr.46.75% 2.21%Net Debt/EBITDA2.66Volume1,452,634Change-0.84%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-18-26ReiteratedBarclaysEqual Weight$20$23
Jun-29-26DowngradeB of A SecuritiesNeutralUnderperform
Jun-03-26ReiteratedBarclaysEqual Weight$30$20
May-14-26DowngradeWells FargoOverweightEqual Weight$19
May-11-26ReiteratedPiper SandlerNeutral$32$21
May-08-26DowngradeNeedhamBuyHold
Apr-21-26DowngradeJefferiesBuyHold$22
Dec-08-25InitiatedBarclaysEqual Weight$30
Aug-12-25UpgradeNeedhamHoldBuy
May-12-25DowngradeJP MorganOverweightNeutral
Latest News· Times ET
Sep-06-26
Sep-01-26
Aug-27-26
Aug-24-26
Aug-15-26
Aug-14-26
Aug-07-26
Aug-06-26
Jul-29-26
Jul-24-26
Jul-22-26
Company

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue730720732
Cost of Goods Sold Incl. D&A381364358
Gross Profit348356374
Selling, General and Administrative Excl. Other14013095
Research and Development948674
Other Operating Expense00-1
Operating Income115140205
Interest Expense272530
Unusual Expense
Non-Operating Income (Expense)13914
Net Income Before Taxes103124189
Income Taxes232630
Consolidated Net Income7798160
Net Income From Continuing Operations7798160
Net Income7798160
EPS (Recurring)1.742.103.29
EPS (Basic, Before Extraordinaries)1.742.103.29
EPS (Diluted)1.692.033.06
EBITDA175212277
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio13.9813.1912.13
Price To Sales Ratio1.421.752.43
Gross Margin47.6749.4451.09
Operating Margin15.7519.4428.01
Net Margin10.5513.6121.86
Shares Outstanding444748
Market Capitalization1,0391,2591,782
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$32.90$28.37$23.84$19.31$14.78 Close Price0.00K141.93K283.86K425.79K567.72KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 16 '26Option Exercise13.3510,000133,500179,203Sep 17
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 16 '26Sale23.9410,000239,404169,203Sep 17
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 02 '26Sale23.633,18775,306169,203Sep 03
PRINS RICHARD KDirectorAug 11 '26Sale20.307,973161,85229,625Aug 12
PETERS WILLIAM JCFO, EVP & TREASURERAug 07 '26Sale22.488,180183,886172,846Aug 11
PETERS WILLIAM JCFO, EVP & TREASURERAug 07 '26Option Exercise19.795,05399,999181,026Aug 11
Zhou RongSENIOR EVP, PRODUCTION CENTERDec 17 '25Option Exercise11.339,787110,887147,830Dec 18
Zhou RongSENIOR EVP, PRODUCTION CENTERDec 17 '25Sale26.209,787256,379138,043Dec 18
Petersen Floyd F.DirectorDec 12 '25Sale25.922,42662,88871,368Dec 15
Petersen Floyd F.DirectorDec 11 '25Sale25.691,73744,62073,794Dec 15
PRINS RICHARD KDirectorNov 25 '25Option Exercise16.694,17969,74839,362Nov 25
PRINS RICHARD KDirectorNov 25 '25Sale27.104,179113,25335,183Nov 25
Petersen Floyd F.DirectorNov 13 '25Option Exercise16.6916,679278,37392,210Nov 17
Petersen Floyd F.DirectorNov 13 '25Sale26.4916,679441,83775,531Nov 17
Petersen Floyd F.DirectorNov 03 '25Sale25.2750012,63375,531Nov 05
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.